Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.

Abstract

Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets. These symptoms were reduced by L-DOPA plus benserazide but the putative D1-receptor agonist SKF 38393-A did not affect tremor and increased the bradykinesia. Neither treatment affected behaviour in normal marmosets. It is suggested that D1-receptor agonists are unlikely to be effective in the treatment of Parkinson's disease.

• Authors: S P Close, A S Marriott, S Pay
• Journal: British journal of pharmacology (Br J Pharmacol) Vol. 85 Issue 2 Pg. 320-2 (Jun 1985) ISSN: 0007-1188 [Print] England
• PMID: 3928007 (Publication Type: Journal Article)

Chemical References

• Benzazepines
• Pyridines
• Levodopa
• 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
• Benserazide
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Topics

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
• 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
• Animals
• Behavior, Animal
• Benserazide (therapeutic use)
• Benzazepines (therapeutic use)
• Callitrichinae
• Levodopa (therapeutic use)
• Male
• Movement Disorders (drug therapy)
• Parkinson Disease, Secondary (chemically induced, drug therapy, physiopathology)
• Pyridines
• Tremor (drug therapy)